JP2000506880A5 - - Google Patents

Download PDF

Info

Publication number
JP2000506880A5
JP2000506880A5 JP1997533220A JP53322097A JP2000506880A5 JP 2000506880 A5 JP2000506880 A5 JP 2000506880A5 JP 1997533220 A JP1997533220 A JP 1997533220A JP 53322097 A JP53322097 A JP 53322097A JP 2000506880 A5 JP2000506880 A5 JP 2000506880A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997533220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000506880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB1997/000650 external-priority patent/WO1997034876A1/en
Publication of JP2000506880A publication Critical patent/JP2000506880A/ja
Publication of JP2000506880A5 publication Critical patent/JP2000506880A5/ja
Ceased legal-status Critical Current

Links

JP9533220A 1996-03-15 1997-03-11 シンノリン誘導体及びその使用 Ceased JP2000506880A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96400533.4 1996-03-15
EP96400533 1996-03-15
PCT/GB1997/000650 WO1997034876A1 (en) 1996-03-15 1997-03-11 Cinnoline derivatives and use as medicine

Publications (2)

Publication Number Publication Date
JP2000506880A JP2000506880A (ja) 2000-06-06
JP2000506880A5 true JP2000506880A5 (enExample) 2004-11-25

Family

ID=8225232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9533220A Ceased JP2000506880A (ja) 1996-03-15 1997-03-11 シンノリン誘導体及びその使用

Country Status (6)

Country Link
US (2) US6514971B1 (enExample)
EP (1) EP0888310B1 (enExample)
JP (1) JP2000506880A (enExample)
AU (1) AU2103097A (enExample)
DE (1) DE69734149T2 (enExample)
WO (1) WO1997034876A1 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU2103097A (en) * 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
ES2291041T3 (es) * 1998-08-13 2008-02-16 Novartis Ag Metodo para tratar enfermedades neovasculares oculares.
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Vegf 억제제로서의 퀴나졸린 유도체
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
KR20020084116A (ko) 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
PT1254138E (pt) 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
MXPA02010222A (es) 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
DE60110802T2 (de) 2000-08-18 2005-10-06 Agouron Pharmaceuticals, Inc., San Diego Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
DE60115069T2 (de) * 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
WO2003063787A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
US7268137B2 (en) * 2002-11-07 2007-09-11 Campochiaro Peter A Ocular therapy
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
WO2004056806A1 (en) 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
EP1633367A2 (en) * 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
UA83509C2 (en) * 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
US20050209247A1 (en) 2003-11-07 2005-09-22 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
US20060004043A1 (en) 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
CA2578996A1 (en) * 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
KR100875870B1 (ko) 2004-10-14 2008-12-26 에프. 호프만-라 로슈 아게 항암제로서의 신규 아자인돌 티아졸리논
JP2008521822A (ja) * 2004-11-29 2008-06-26 エントレメッド インコーポレイテッド 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
EP1833803A4 (en) * 2005-01-03 2009-08-05 Myriad Genetics Inc PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
EP2465857B1 (en) 2005-05-17 2014-06-04 Novartis AG Methods for synthesizing heterocyclic compounds
US20060264439A1 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
NZ567550A (en) 2005-11-29 2011-08-26 Novartis Ag Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US10968290B2 (en) 2017-03-28 2021-04-06 Exxonmobil Chemical Patents Inc. Metallocene-catalyzed polyalpha-olefins
US11078308B2 (en) 2018-02-12 2021-08-03 Exxonmobil Chemical Patents Inc. Processes to produce poly alpha-olefin trimers
US11021553B2 (en) 2018-02-12 2021-06-01 Exxonmobil Chemical Patents Inc. Metallocene dimer selective catalysts and processes to produce poly alpha-olefin dimers
US11084894B2 (en) 2018-02-12 2021-08-10 Exxonmobil Chemical Patents Inc. Catalyst systems and processes for poly alpha-olefin having high vinylidene content
EP3784677A4 (en) 2018-04-26 2022-03-09 ExxonMobil Chemical Patents Inc. NON-COORDINATING ANION TYPE ACTIVATORS WITH A CATION WITH LARGE ALKYL GROUPS
US11059791B2 (en) 2019-04-25 2021-07-13 Exxonmobil Chemical Patents Inc. Non-coordinating anion type benzimidazolium activators
WO2021030045A1 (en) 2019-08-09 2021-02-18 Exxonmobil Chemical Patents Inc. Process to produce low viscosity polyalphaolefins using non-aromatic-hydrocarbon soluble activators
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途
US11661465B2 (en) 2019-10-28 2023-05-30 Exxonmobil Chemical Patents Inc. Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith
US11572423B2 (en) 2019-12-11 2023-02-07 Exxonmobil Chemicals Patents Inc. Processes for introduction of liquid activators in olefin polymerization reactions
US11584707B2 (en) 2019-12-16 2023-02-21 Exxonmobil Chemical Patents Inc. Non-coordinating anion type activators containing cation having aryldiamine groups and uses thereof
CN115485311B (zh) 2020-02-24 2024-12-06 埃克森美孚化学专利公司 用于生产乙烯叉基封端的聚α-烯烃的柄型-双(茚-2-基)催化剂
US11746163B2 (en) 2021-01-05 2023-09-05 Exxonmobil Chemical Patents Inc. Isohexane-soluble unsaturated alkyl anilinium tetrakis(perfluoroaryl)borate activators
CN119638634B (zh) * 2023-09-18 2026-01-30 上海赛默罗生物科技有限公司 噌啉-2-氧化物类化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2594438B1 (fr) 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US5182291A (en) 1986-02-14 1993-01-26 Sanofi Pyrozala-pyridyl aminoabkoxyphenol compounds
US5215988A (en) 1986-02-14 1993-06-01 Sanofi Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same
IL87181A (en) 1987-08-07 1993-08-18 Sanofi Sa Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
AU2103097A (en) * 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000508223A5 (enExample)
JP2001504338A5 (enExample)
JP2000500076A5 (enExample)
JP2000506880A5 (enExample)
JP2000502472A5 (enExample)
JP2000507939A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000505983A5 (enExample)
JP2000501876A5 (enExample)
JP2000512483A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000514801A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)
JP2000500184A5 (enExample)
JP2000500318A5 (enExample)